000275967 001__ 275967
000275967 005__ 20250126000533.0
000275967 0247_ $$2doi$$a10.1016/j.neuroimage.2025.121001
000275967 0247_ $$2pmid$$apmid:39798829
000275967 0247_ $$2ISSN$$a1053-8119
000275967 0247_ $$2ISSN$$a1095-9572
000275967 0247_ $$2altmetric$$aaltmetric:172948305
000275967 037__ $$aDZNE-2025-00163
000275967 041__ $$aEnglish
000275967 082__ $$a610
000275967 1001_ $$aBauer, Theresa$$b0
000275967 245__ $$aPragmatic algorithm for visual assessment of 4-Repeat tauopathies in [18F]PI-2620 PET Scans.
000275967 260__ $$aOrlando, Fla.$$bAcademic Press$$c2025
000275967 3367_ $$2DRIVER$$aarticle
000275967 3367_ $$2DataCite$$aOutput Types/Journal article
000275967 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737367261_4999
000275967 3367_ $$2BibTeX$$aARTICLE
000275967 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275967 3367_ $$00$$2EndNote$$aJournal Article
000275967 520__ $$aStandardized evaluation of [18F]PI-2620 tau-PET scans in 4R-tauopathies represents an unmet need in clinical practice. This study aims to investigate the effectiveness of visual evaluation of [18F]PI-2620 images for diagnosing 4R-tauopathies and to develop a straight-forward reading algorithm to improve objectivity and data reproducibility.A total of 83 individuals with [18F]PI-2620 PET scans were included. Participants were classified as probable 4R-tauopathies (n = 29), Alzheimer's disease (AD) (n = 20), α-synucleinopathies (n = 15), and healthy controls (n = 19) based on clinical criteria. Visual assessment of tau-PET scans (choice: 4R-tauopathy, AD-tauopathy, no-tauopathy) was conducted using either 20-40-minute or 40-60-minute intervals, with raw (common) and cerebellar grey matter scaled standardized reading settings (intensity-scaled). Two readers evaluated scans independently and blinded, with a third reader providing consensus in case of discrepant primary evaluation. A regional analysis was performed using the cortex, basal ganglia, midbrain, and dentate nucleus. Sensitivity, specificity, and interrater agreement were calculated for all settings and compared against the visual reads of parametric images (0-60-minutes, distribution volume ratios, DVR).Patients with 4R-tauopathies in contrast to non-4R-tauopathies were detected at higher sensitivity in the 20-40-minute frame (common: 79%, scaled: 76%) compared to the 40-60-minute frame (common: 55%, scaled: 62%), albeit with reduced specificity in the common setting (20-40-min: 78%, 40-60-min: 95%), which was ameliorated in the intensity-scaled setting (20-40-min: 91%, 40-60-min: 96%). Combined assessment of multiple brain regions did not significantly improve diagnostic sensitivity, compared to assessing the basal ganglia alone (76% each). Evaluation of intensity-scaled parametric images resulted in higher sensitivity compared to intensity-scaled static scans (86% vs. 76%) at similar specificity (89% vs. 91%).Visual reading of [18F]PI-2620 tau-PET scans demonstrated reliable detection of 4R-tauopathies, particularly when standardized processing methods and early imaging windows were employed. Parametric images should be preferred for visual assessment of 4R-tauopathies.
000275967 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000275967 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000275967 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000275967 650_7 $$2Other$$aReading algorithm
000275967 650_7 $$2Other$$aTau-PET
000275967 650_7 $$2Other$$aTauopathies
000275967 650_7 $$2Other$$aVisual read
000275967 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b1$$udzne
000275967 7001_ $$aZaganjori, Mirlind$$b2
000275967 7001_ $$0P:(DE-2719)9002620$$aBernhardt, Alexander M$$b3$$udzne
000275967 7001_ $$0P:(DE-2719)9002626$$aJäck, Alexander$$b4$$udzne
000275967 7001_ $$aStöcklein, Sophia$$b5
000275967 7001_ $$aScheifele, Maximilian$$b6
000275967 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b7$$udzne
000275967 7001_ $$0P:(DE-2719)2812285$$avan Eimeren, Thilo$$b8$$udzne
000275967 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b9$$udzne
000275967 7001_ $$0P:(DE-2719)2814810$$aSabri, Osama$$b10$$udzne
000275967 7001_ $$aBarthel, Henryk$$b11
000275967 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b12$$udzne
000275967 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b13$$udzne
000275967 7001_ $$aFranzmeier, Nicolai$$b14
000275967 7001_ $$0P:(DE-2719)9001652$$aGnörich, Johannes$$b15$$eLast author$$udzne
000275967 7001_ $$aTauopathies, German Imaging Initiative for$$b16$$eCollaboration Author
000275967 773__ $$0PERI:(DE-600)1471418-8$$a10.1016/j.neuroimage.2025.121001$$gVol. 306, p. 121001 -$$p121001$$tNeuroImage$$v306$$x1053-8119$$y2025
000275967 8564_ $$uhttps://pub.dzne.de/record/275967/files/DZNE-2025-00163%20SUP.docx
000275967 8564_ $$uhttps://pub.dzne.de/record/275967/files/DZNE-2025-00163.pdf$$yOpenAccess
000275967 8564_ $$uhttps://pub.dzne.de/record/275967/files/DZNE-2025-00163%20SUP.doc
000275967 8564_ $$uhttps://pub.dzne.de/record/275967/files/DZNE-2025-00163%20SUP.odt
000275967 8564_ $$uhttps://pub.dzne.de/record/275967/files/DZNE-2025-00163%20SUP.pdf
000275967 8564_ $$uhttps://pub.dzne.de/record/275967/files/DZNE-2025-00163.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000275967 909CO $$ooai:pub.dzne.de:275967$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000275967 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000275967 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002620$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000275967 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002626$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000275967 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000275967 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812285$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000275967 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811239$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000275967 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814810$$aExternal Institute$$b10$$kExtern
000275967 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000275967 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000275967 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001652$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000275967 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000275967 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000275967 9141_ $$y2025
000275967 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000275967 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROIMAGE : 2022$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T08:47:40Z
000275967 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T08:47:40Z
000275967 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROIMAGE : 2022$$d2024-12-16
000275967 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000275967 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000275967 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-16$$wger
000275967 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000275967 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000275967 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000275967 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x2
000275967 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x3
000275967 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x4
000275967 980__ $$ajournal
000275967 980__ $$aVDB
000275967 980__ $$aUNRESTRICTED
000275967 980__ $$aI:(DE-2719)1110007
000275967 980__ $$aI:(DE-2719)1111015
000275967 980__ $$aI:(DE-2719)1111016
000275967 980__ $$aI:(DE-2719)1011202
000275967 980__ $$aI:(DE-2719)5000022
000275967 9801_ $$aFullTexts